Free Trial
NASDAQ:VERU

Veru (VERU) Stock Price, News & Analysis

Veru logo
$2.08 -0.02 (-0.72%)
As of 02:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Veru Stock (NASDAQ:VERU)

Advanced

Key Stats

Today's Range
$2.03
▼
$2.14
50-Day Range
$2.06
▼
$2.66
52-Week Range
$2.03
▼
$7.33
Volume
93,794 shs
Average Volume
658,637 shs
Market Capitalization
$35.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.50
Consensus Rating
Moderate Buy

Company Overview

Veru Inc. is a biopharmaceutical company focused on developing medicines for metabolic diseases and cancer. Its research programs include enobosarm, which is being studied to help preserve muscle during weight loss associated with GLP-1 medicines, as well as candidates investigated for breast and prostate cancer.

The company has also developed sabizabulin, an investigational drug studied for cancer treatment. These medicines remain development-stage products; Veru’s clinical programs and priorities may change as research progresses.

Historically, Veru was known as The Female Health Company and developed FC2, a female condom distributed in the United States and internationally. The company adopted the Veru name in 2017 as it expanded its focus into pharmaceuticals.

AI Generated. May Contain Errors.

Veru Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

VERU MarketRank™: 
1.725898421955 of 5 stars

Veru scored higher than 35% of companies evaluated by MarketBeat, and ranked 691st out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Veru has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Veru has a consensus price target of $24.50, representing about 1,086.4% upside from its current price of $2.07.

  • Amount of Analyst Coverage

    Veru has only been the subject of 3 research reports in the past 90 days.

  • Read more about Veru's stock forecast and price target.
  • Earnings Growth

    Earnings for Veru are expected to decrease in the coming year, from ($1.04) to ($1.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Veru is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Veru is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Veru has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Veru's valuation and earnings.
  • Percentage of Shares Shorted

    10.25% of the float of Veru has been sold short.
  • Short Interest Ratio / Days to Cover

    Veru has a short interest ratio ("days to cover") of 13.25, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Veru has recently increased by 2.29%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Veru does not currently pay a dividend.

  • Dividend Growth

    Veru does not have a long track record of dividend growth.

  • News Sentiment

    Veru has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Veru this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for VERU on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Veru to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Veru insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    14.20% of the stock of Veru is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    47.16% of the stock of Veru is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Veru's insider trading history.
Receive VERU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VERU Stock News Headlines

Veru (NASDAQ:VERU) Upgraded at Wall Street Zen
A Nasdaq drone company just landed a deal with a Philippine billionaire's group
A Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billionaire Enrique Razon Jr.'s business empire. The Razon Group spans ports, energy, mining, utilities and infrastructure, and its affiliated port operator generated over $3.2 billion in 2025 revenue. The deal lays the groundwork for drone manufacturing in the Philippines, with potential expansion across Southeast Asia. The company was also selected for a five-year Canadian Armed Forces contract covering 100 systems, with options for up to 4,900 more. It supplies the U.S. Army, holds a U.S. Air Force Special Operations Command contract, and recently announced a $10 million strategic investment from Unusual Machines.tc pixel
Veru (NASDAQ:VERU) Rating Lowered to Strong Sell at Wall Street Zen
See More Headlines

VERU Stock Analysis - Frequently Asked Questions

Veru's stock was trading at $2.14 on January 1st, 2026. Since then, VERU stock has decreased by 3.5% and is now trading at $2.0650.

Veru Inc. (NASDAQ:VERU) issued its quarterly earnings data on Monday, August, 10th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.02.
Read the conference call transcript
.

Veru shares reverse split on the morning of Monday, August 11th 2025.The 1-10 reverse split was announced on Wednesday, August 6th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 8th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Veru investors own include NVIDIA (NVDA), NIO (NIO), Tesla (TSLA), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Plug Power (PLUG) and PayPal (PYPL).

Company Calendar

Last Earnings
8/10/2026
Today
11/16/2026
Next Earnings (Estimated)
11/26/2026
Fiscal Year End
9/30/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:VERU
CIK
863894
Employees
20
Year Founded
1896

Price Target and Rating

High Price Target
$25.00
Low Price Target
$24.00
Potential Upside/Downside
+1,080.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.69)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$22.73 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-47.58%
Return on Assets
-35.83%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.42
Quick Ratio
4.42

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.25 per share
Price / Book
1.66

Miscellaneous

Outstanding Shares
17,050,000
Free Float
14,629,000
Market Cap
$35.38 million
Optionable
Optionable
Beta
-1.20

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:VERU) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners